Clinical Trial Detail

NCT ID NCT02315326
Title Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

diffuse large B-cell lymphoma

central nervous system lymphoma

Therapies

Ibrutinib

Age Groups: adult

No variant requirements are available.